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osity, comorbid burden using a method of risk adjustment based
on pharmacy claims, and Part D uptake after adjusting for
patients’ demographic characteristics, characteristics of pre-Part
D prescription use (average 2005 annual copayments, number of
prescriptions, drug utilization in pill-days, number of treatment
classes as reported in the store data), pre-Part D Medicaid eligi-
bility, and zip code linked USA Census data. RESULTS: After
multivariate adjustment, each 10% increase in 2005 insurance
generosity was associated with a 16% lower likelihood of Part D
utilization and each standard deviation increase in comorbid
score was associated with an 8% greater likelihood of Part D
utilization. Beneﬁciaries with the lowest yet positive insurance
generosity with the greatest comorbid burden were up to 2.5
times more likely to utilize Part D than people who had generous
insurance and were the healthiest before the introduction of the
program (60.65% vs. 37.56%, p < 0.001). Results were robust
to numerous sensitivity analyses. CONCLUSION: We ﬁnd sig-
niﬁcantly higher rates of beneﬁt adoption among subjects with
low pre-Part D prescription coverage and high pre-Part D comor-
bid burden. Our ﬁndings highlight the fact that implementation
and uptake of changes in health policy are seldom uniform.
These results also may be useful in welfare analyses of Part D,
and they demonstrate the importance of considering non-random
selection into Part D when considering the impact of Part D on
processes or outcomes of care.
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OBJECTIVE: To evaluate the effect of Medicare new drug beneﬁt
(Part D) on utilization of psychotropic medications and the con-
sequent ﬁnancial burden for elderly. METHODS: The effect of
Medicare Part D was measured using 24 months pharmacy
claims collected from one of the largest retail pharmacy chains in
the United States. Among the approximately 70 million individu-
als who ﬁlled prescriptions at the pharmacy chain in 2006, 11%
were 65 years or older. Segmented regression of interrupted
time series analysis was employed to evaluate population level
changes in the utilization of three most commonly used psycho-
tropic therapeutic categories among elderly, namely antidepres-
sants, antipsychotics and benzodiazepines. RESULTS: Since Part
D came into effect, the proportion of out-of-pocket payment in
total pharmacy reimbursement decreased 18% for antidepres-
sants (net saving: $4.5 per prescription) and 21% for antipsy-
chotics (net saving: $5.7 per prescription). In contrast, the out-
of-pocket share the elderly paid for benzodiazepines increased
19% (net increase: $2.8 per prescription). Part D implementation
was associated with signiﬁcant month-to-month increase in use
of antidepressants [1679 prescriptions per month (95%CI:719,
2639)] and antipsychotics [567 prescriptions per month (95%
CI:413, 720)]. By December 2006, the antidepressant and antip-
sychotic prescriptions ﬁlled by seniors grew 7% (from 273,166
to 293,590 prescriptions per month, P < 0.001) and 18% (from
41,079 to 48,276 prescriptions per month, P < 0.001) respec-
tively as compared to the expected level estimated based on prior
Part D trend. In contrast, Part D led to an immediate and sus-
tained drop of 5% (from 238,961 to 226,622 prescriptions per
month, P < 0.001) in benzodiazepine prescriptions ﬁlled by
elderly. CONCLUSION: Our ﬁndings revealed that Medicare
Part D improved the access to psychotropic medications covered
under plan through reducing out-of-pocket expenses. However,
the ﬁnancial burden related to psychotropic medications
excluded from the Part D formulary, such as benzodiazepines,
has signiﬁcantly increased.
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The aim of this study was to assess the Rasch measurement
properties of the EQ-5D in respondents with most prevalent
chronic conditions. Medical Expenditures Panel Survey (MEPS)
respondents’ age  18 with complete EQ-5Ds from 2003 were
extracted (n = 19,439). Eleven subgroups were identiﬁed using
the primary ICD-9-CM code for the top 10 chronic conditions
(hypertension, diabetes, depression, back disorder, arthropathy,
cholesterol, asthma, sinusitis, anxiety and joint disorder) as well
as healthy persons (n = 8021). Respondents with perfect scores
demonstrating ceiling (n = 3911) and ﬂoor effects (n = 3) were
removed to ensure uncertainty in the responses. Coding reﬂected
that higher scores represent healthier respondents. The Rasch
rating scale model was used to estimate one set of thresholds for
all items. Unidimensionality was assessed using a z-score ﬁt sta-
tistic, point-biserial correlations and Rasch residual factor analy-
sis. Differential item functioning (DIF) was investigated in a
pooled analysis of the 11 subgroups. Qualitative advances of the
thresholds and positive point-biserial correlations were found
on the EQ-5D items in all subgroups. Residual factor analysis
revealed that a single factor explained between 74.9% and
94.4% of the variance. Further, respondents with different
diseases demonstrated different orders of item difﬁculty. How-
ever, the item “anxiety/depression” consistently showed misﬁt
(z-score > 2.0) in all subgroups. Overall, differential item func-
tioning was found across the 11 subgroups, suggesting that
respondents with different health conditions endorsed items with
different frequency. For the most part, items in the EQ-5D con-
tribute to a single underlying construct and may be used to
evaluate different disease conditions. However, consistent item
misﬁt of the “anxiety/depression” item in all subgroups suggests
that a possible modiﬁcation on this item may be needed.
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The value of qualitative research in the development of Patient-
Reported Outcome (PRO) measures has been recognized for
many years. Very little information is available, however, in the
PRO ﬁeld on the conduct and analysis of qualitative research
compared to the plethora of literature that is readily available on
psychometrics. More recently, the focus has been placed on the
concepts being measured and their meaning, and not in terms
of correlation coefﬁcients or factorial structure, but in their
authenticity for patients. This paper that is authored by an inter-
national, interdisciplinary group of psychologists, psychometri-
cians, regulatory experts, a physician, and a sociologist presents
a method for developing PROs that are based on a foundation of
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